VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2...
June 04 2020 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced
new data implicating the potential of its proprietary anti-MOSPD2
antibodies for treatment of rheumatoid arthritis (RA). VBL's study
entitled “MOSPD2: A novel therapeutic target for the treatment of
rheumatoid arthritis,” is being presented today at the European
League Against Rheumatism (EULAR) 2020 E-Congress.
VBL's new data highlight several key findings:
- Clinical relevance for RA:
Biopsies from RA patients demonstrate strong staining for monocytes
expressing MOSPD2. Monocytes are immune cells that play a pivotal
role in the progression of various inflammatory diseases. VBL's
antibodies can inhibit monocyte migration by up to 90% in a mouse
model.
- MOSPD2 plays a key role in RA: Mice in which
the MOSPD2 gene was knocked out essentially do not develop disease
in the Collagen Antibody-Induced Arthritis model for RA.
- Therapeutic potential: Treatment with
anti-MOSPD2 mAb significantly inhibited arthritis progression in
the Collagen-Induced Arthritis model (p<0.005). The treatment
reduced >50% of disease severity and blocked further disease
progression.
- Differentiation: Anti-MOSPD2 demonstrated
higher activity than anti-TNFa in the advanced phase of the
disease.
"These encouraging results may open new possibilities for
treatment of anti-MOSPD2 antibodies for RA," said Eyal Breitbart,
Ph.D., VP Research and Operations of VBL Therapeutics."We continue
to see a clear pattern across multiple indications – by inhibiting
monocyte migration, our proprietary antibodies lead to meaningful
and durable benefit in various models of chronic inflammatory
diseases.”
The new results add to a growing body of data demonstrated
activity of VBL's antibodies in models of multiple sclerosis,
nonalcoholic steatohepatitis and colitis. VBL continues to advance
lead candidate VB-601 towards a first-in-man study, which is
expected to begin in 2021.
For a link to VBL's presentation at the EULAR conference, see:
Poster Presentation
About VBL's VB-600 PlatformVBL is conducting
two parallel drug development programs that are exploring the
potential of MOSPD2 (motile sperm domain-containing protein 2), a
protein that VBL has identified as a key regulator of cell
motility, as a therapeutic target for inflammatory diseases and
cancer. Our VB-600 platform comprises classical anti-MOSPD2
monoclonal antibodies for inflammatory indications, as well as
bi-specific antibody candidates for oncology.
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. VBL’s lead oncology product
candidate, ofranergene obadenovec (VB-111), is a first-in-class,
targeted anti-cancer gene-therapy agent that is being developed to
treat a wide range of solid tumors. It is conveniently administered
as an IV infusion once every two months. It has been observed to be
well-tolerated in >300 cancer patients and demonstrated activity
signals in a VBL-sponsored “all comers” phase 1 trial as well as in
three VBL-sponsored tumor-specific phase 2 studies. Ofranergene
obadenovec is currently being studied in a VBL-sponsored phase 3
potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including MOSPD2, including their clinical development,
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, the risk that historical clinical trial results may not
be predictive of future trial results, the impact of the COVID-19
pandemic on our business, operations, clinical trials, supply
chain, strategy, goals and anticipated timelines and clinical
results, that our financial resources do not last for as long as
anticipated, and that we may not realize the expected benefits of
our intellectual property protection. A further list and
description of these risks, uncertainties and other risks can be
found in our regulatory filings with the U.S. Securities and
Exchange Commission, including in our annual report on Form 20-F
for the year ended December 31, 2019, and subsequent filings
with the SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024